ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Northwest Biotherapeutics Adds Production Capacity at UK Facility
March 18, 2021Dendritic cell vaccine production capacity for personalized immune therapies increases from about 4 - 6 patients per month to about 40 - 45 patients per month. -
Northwest Biotherapeutics Acquires Flaskworks
September 03, 2020Northwest Biotherapeutics announced the Company has acquired Flaskworks, a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®. -
NW Bio Accelerating Sawston Plant Phase I Buildout
September 02, 2020Construction crews working double shifts to accelerate completion despite COVID effects. -
NW Bio Announces $5 Million Bridge Funding
November 14, 2018Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers
Pharma Sources Insight January 2025
